Daily Judi: Tuesday, November 22, 2022
Every day we scan the headlines for the best items that engage the clinical trial ecosystem, workflow solutions, and more—all the latest news you need to know. Here are today's stories:
In light of Eisai and Biogen's new drug, lecanemab, the Guardian's Ian Sample looks at this historic moment in the global fight against Alzheimer’s.
Lisa M. Krieger of the San Jose Mercury News discusses a new Paxlovid study at Stanford’s Post-Acute COVID-19 Syndrome Clinic, in hopes it reduces the effects of long COVID.
A phase 3 clinical trial has shown positive results for a new brain cancer vaccine (DCVax-L). The trial was conducted in part at King's College Hospital in London, and results were published this week in JAMA Oncology. (Medical Xpress)
Our Culture
“Technology and process improvements will continue to decrease our timelines on creating specifications by 50 percent or more, this year. The more we continue to improve the faster we will be.”
–Jamie, Trial Delivery
About Judi
Judi speeds and improves the world's clinical trial workflows. Our cloud-based platform has 120,000 users across 168 countries. We eliminate the chaos so clinical teams can focus on the patient, rather than the process. We are a SOC 2 Type II certified collaboration platform.
